source
- Merck and Moderna disclose phase 3 cancer vaccine data early after leak, showing improved recurrence-free survival with KeytrudaMerck & Co. and Moderna were forced to release their phase 3 trial results for the intismeran autogene cancer vaccine two days ahead of schedule after an unexpected leak of the data ahead of the ES…
- AstraZeneca says phase 3 ADC shows strong overall survival despite missing progression-free survival endpointAstraZeneca executives emphasized that the detailed data from their phase 3 study of the next‑generation antibody‑drug conjugate are robust enough to be presented to regulators, even though the tri…